These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6151203)

  • 41. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
    Citrome L; Jaffe A; Levine J
    Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neuroleptic effects on serine and glycine metabolism.
    Baruah S; Waziri R; Sherman A
    Biol Psychiatry; 1993 Oct; 34(8):544-50. PubMed ID: 7903868
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone.
    Olfson M; Marcus SC; Ascher-Svanum H
    Schizophr Bull; 2007 Nov; 33(6):1379-87. PubMed ID: 17470444
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Depot bromperidol decanoate for schizophrenia.
    Wong D; Adams CE; David A; Quraishi SN
    Cochrane Database Syst Rev; 2004; (3):CD001719. PubMed ID: 15266450
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bromperidol decanoate (depot) for schizophrenia.
    Purgato M; Adams CE
    Cochrane Database Syst Rev; 2011 Sep; (9):CD001719. PubMed ID: 21901678
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fluphenazine levels during maintenance treatment of recent-onset schizophrenia: relation to side effects, psychosocial function and depression.
    Gitlin MJ; Nuechterlein KH; Mintz J; Fogelson D; Bartzokis G; Ventura J; Subotnik K; Aravagiri M
    Psychopharmacology (Berl); 2000 Mar; 148(4):350-4. PubMed ID: 10928306
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effects of typical and atypical neuroleptics on mitogen-induced T lymphocyte responsiveness.
    Rapaport MH; McAllister CG; Kirch DG; Pickar D
    Biol Psychiatry; 1991 Apr; 29(7):715-7. PubMed ID: 1711382
    [No Abstract]   [Full Text] [Related]  

  • 48. Clinical symptomatology and drug compliance in schizophrenic patients.
    Bartkó G; Herczeg I; Zádor G
    Acta Psychiatr Scand; 1988 Jan; 77(1):74-6. PubMed ID: 2894746
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A double-blind, controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W; Boisvert D; Bradwejn J
    Psychopharmacol Bull; 1984; 20(1):108-9. PubMed ID: 6371871
    [No Abstract]   [Full Text] [Related]  

  • 50. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
    Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
    Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Initial improvement as predictor of outcome of neuroleptic treatment.
    Nedopil N; Rüther E
    Pharmacopsychiatria; 1981 Nov; 14(6):205-7. PubMed ID: 6119712
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neuroleptic levels by radioreceptor assay and clinical response during treatment of acute exacerbation of schizophrenia--some preliminary findings.
    Greenberg JS; Brown WA; Laughren TP; Krantz J
    Psychopharmacol Bull; 1983; 19(1):74-6. PubMed ID: 6131470
    [No Abstract]   [Full Text] [Related]  

  • 53. Effect of antipsychotic medication on speed of information processing in schizophrenic patients.
    Braff DL; Saccuzzo DP
    Am J Psychiatry; 1982 Sep; 139(9):1127-30. PubMed ID: 6126128
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 12-month study of haloperidol decanoate in chronic schizophrenic patients.
    Gelders YG; Reyntijens AJ; Ash CW; Aerts TJ
    Int Pharmacopsychiatry; 1982; 17(4):247-54. PubMed ID: 7185769
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neuroleptic drug effect on platelet monoamine oxidase and plasma amine oxidase in schizophrenia.
    Baron M; Gruen R; Levitt M; Kane J
    Psychiatry Res; 1982 Oct; 7(2):179-87. PubMed ID: 6128754
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A double-blind comparison of fluspirilene and fluphenazine decanoate in schizophrenia.
    Russell N; Landmark J; Merskey H; Turpin T
    Can J Psychiatry; 1982 Nov; 27(7):593-6. PubMed ID: 7172160
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.
    Purdon SE; Jones BD; Stip E; Labelle A; Addington D; David SR; Breier A; Tollefson GD
    Arch Gen Psychiatry; 2000 Mar; 57(3):249-58. PubMed ID: 10711911
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient.
    Aruna AS; Murungi JH
    Ann Pharmacother; 2005 Jun; 39(6):1131-5. PubMed ID: 15840734
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cocaine use by schizophrenic outpatients who receive depot neuroleptic medication.
    Stone AM; Greenstein RA; Gamble G; McLellan AT
    Hosp Community Psychiatry; 1993 Feb; 44(2):176-7. PubMed ID: 8432504
    [No Abstract]   [Full Text] [Related]  

  • 60. [A differential effect profile of neuroleptic therapy of acute schizophrenic patients? Results of a clinico-naturalistic study].
    Schmidt LG; Siemetzki H
    Nervenarzt; 1988 Dec; 59(12):721-6. PubMed ID: 2905770
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.